The overall survival of patients with EGFR‐mutated lung cancer has improved remarkably from one year to approximately three to four years after the introduction of EGFR tyrosine kinase inhibitors (EGFR‐TKIs).2, 3, 4, 5, 6, 7. The gene discussed is EGFR; the disease is lung carcinoma.